Madrigal's Rezdiffra (Resmetirom): The First MASH Drug Is Already on the Market

Last updated July 24, 2026: This article originally described an “August 14 PDUFA date” for resmetirom as an upcoming event and stated that MASH had “no approved treatments.” Both claims were incorrect. The FDA approved resmetirom (Rezdiffra) on March 14, 2024 for noncirrhotic NASH/MASH with moderate to advanced liver fibrosis (F2-F3). The drug has been on the market for over two years. The article has been rewritten to reflect the drug’s approved status and current commercial trajectory.

The FDA approved Madrigal Pharmaceuticals’ resmetirom (Rezdiffra) on March 14, 2024 — the first and only medication approved by the FDA for the treatment of NASH (also known as MASH) with moderate to advanced liver fibrosis. It was a historic milestone in hepatology: the culmination of a 30-year hunt for a fatty liver disease treatment.

The disease nobody talks about

MASH is the severe form of MASLD (formerly NASH). Fat builds up in the liver, causes inflammation and scarring, and can progress to cirrhosis, liver failure, and liver cancer. For 30 years, the standard of care was “lose weight and exercise” — effective advice that most patients couldn’t follow.

The market is enormous. An estimated 5 million Americans have MASH with F2-F3 fibrosis — the stage Rezdiffra targets. Global prevalence is estimated at 100 million. Intercept Pharmaceuticals tried (and failed) with obeticholic acid. Genfit tried (and failed) with elafibranor. Madrigal was the first to succeed with positive Phase 3 data.

The data behind the approval

The MAESTRO-NASH trial enrolled 966 patients with F2 or F3 fibrosis. At 52 weeks:

• MASH resolution: 26% of resmetirom patients vs. 14% on placebo (p < 0.001)
• Fibrosis improvement: 24% vs. 14% on placebo (p = 0.004)
• LDL cholesterol reduction: 16% (a bonus — MASH patients have cardiovascular risk)

The approval was granted under the accelerated approval pathway, based on improvement of NASH and liver scarring (fibrosis). Madrigal needs confirmatory eGFR data from the ongoing MAESTRO-NASH-OUTCOMES trial for full approval.

The commercial reality

Rezdiffra launched into an empty market as the first and only MASH drug. Madrigal has been building the commercial infrastructure from scratch — educating hepatologists and primary care physicians about a disease most had never formally diagnosed.

Madrigal’s stock closed at $543.35 on July 24, 2026, with a market cap of approximately $10 billion. The stock reflects significant launch expectations. The key question for investors is whether prescription growth justifies the valuation.

What we’re watching

1. Launch metrics: Prescription data through 2025–2026 indicates early adoption by hepatologists. The pace of prescriber expansion and weekly prescription volume will determine whether Madrigal hits consensus revenue estimates.
2. Confirmatory trial: The MAESTRO-NASH-OUTCOMES trial is ongoing. If confirmatory data does not verify clinical benefit, the FDA could withdraw approval. This is the long-term risk.
3. Competition: Akero Therapeutics (AKRO) and 89bio (ETNB) are behind with FGF21 analogs. BridgeBio’s acoramidis was also approved for ATTR-CM but has a different mechanism. The MASH competitive landscape is still forming.
4. Label expansion: Madrigal may pursue expanded indications (e.g., earlier fibrosis stages, or combination therapy) that could broaden the addressable market.

MASH is a story we’ve been following since before the approval. The next chapter is launch execution — whether Madrigal can turn the first-mover advantage into a durable franchise.

What It Means for the Trade

MDGL at roughly $10 billion market cap ($543.35) is priced as a launch-velocity story: the drug is approved, the market is enormous (5 million F2-F3 Americans, 100 million globally), and the entire valuation question is whether prescription growth compounds fast enough to justify a premium. First-mover advantage in MASH is genuinely valuable — hepatologists are building diagnostic and treatment pathways around Rezdiffra — but it is not a moat: Akero and 89bio have FGF21 data behind them, and any successful challenger converts pricing power into a market-share fight. The catalysts in order: quarterly prescription and prescriber-expansion trends against consensus revenue estimates, label-expansion decisions (earlier fibrosis, combinations), and the MAESTRO-NASH-OUTCOMES readout, which is both the de-risking event (confirmatory full approval) and the tail risk (withdrawal if clinical benefit is not verified).

Mechanism and Market Context

Resmetirom is a liver-directed thyroid hormone receptor-beta agonist: selective THR-beta activation in hepatocytes raises lipid metabolism and mitochondrial function in the liver specifically, avoiding the cardiac TH effects that made systemic thyroid hormone unusable. The MAESTRO-NASH numbers are the evidence base: 26% MASH resolution versus 14% placebo and 24% fibrosis improvement versus 14%, both statistically robust at 52 weeks in 966 patients. The LDL reduction (16%) matters commercially because MASH patients carry elevated cardiovascular risk, so a drug that improves the liver without worsening the lipid profile answers the first objection cardiologists raise. The competitive backdrop is the race for second position: an FGF21 approval would split the market by mechanism, while combinations are where the field’s leaders expect the standard of care to end up.

Risks and What Could Go Wrong

1. MAESTRO-NASH-OUTCOMES is the existential tail: failure to verify clinical benefit can pull the approval entirely under the accelerated pathway.
2. A successful FGF21 challenger compresses pricing power years before Madrigal’s outcomes data mature.
3. High-value MASH patients overlap heavily with GLP-1 populations; a dominant incretin label expansion (e.g., in MASH itself) would redraw the market entirely.
4. At $10 billion on launch-stage revenue, any quarterly prescription shortfall gets punished violently — the multiple leaves no room for a slow quarter.